No. 23A344

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al.

Lower Court: Federal Circuit
Docketed: 2023-10-17
Status: Presumed Complete
Type: A
Experienced Counsel
Tags: KSR-standard obviousness patent-law pharmaceutical-patents predictable-result prior-art
Key Terms:
Patent
Latest Conference: N/A
Question Presented (from Petition)

This is an application for an extension of time to file a petition for a writ of certiorari, not a petition itself. The document does not contain a "Question(s) Presented" section in the formal sense found in petitions for certiorari.

Question not identified.

Question Presented (AI Summary)

Whether the Federal Circuit's obviousness analysis complies with the Supreme Court's standard in KSR International Co. v. Teleflex Inc. by requiring that prior art combinations yield more than a predictable result, or whether the court may find claims obvious based on a flawed methodology that deviates from KSR's framework

Docket Entries

2023-10-18
Application (23A344) granted by The Chief Justice extending the time to file until January 12, 2024.
2023-10-13
Application (23A344) to extend the time to file a petition for a writ of certiorari from November 14, 2023 to January 12, 2024, submitted to The Chief Justice.

Attorneys

Vanda Pharmaceuticals Inc.
Paul Whitfield HughesMcDermott Will & Emery, Petitioner